A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Recruiting now Phase 1/2 NCT07258407
Run by T.O.A.D. Oncology SA · for 18 and older · Men
What this study is about
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Who can join (things the study team will check)
✅ You may be able to join if…
- Patient must fully understand the study requirements and voluntarily sign informed consent.
- PSMA-expressing metastatic CRPC with documented progression based on serum PSA, RECIST 1.1 with PCWG3, and/or bone disease.
- At least one measurable metastatic lesion per RECIST 1.1.
- Adequate organ function.
- Prior orchiectomy and/or ongoing androgen deprivation therapy.
- Prior treatment with at least one androgen receptor pathway inhibitor (ARPI) drug.
🚫 You may not be able to join if…
- Previous treatment with strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, or hemi-body irradiation, within 6 months before treatment.
- Systemic anticancer therapy including an investigational agent within 28 days before treatment.
- Known hypersensitivity to the components of TD001, its analogs, or excipients.
- Current dyspnea at rest, other disease requiring continuous oxygen therapy, or history of pneumonitis
Where this trial is running
- Yale University, Yale Cancer Center, New Haven, Connecticut, United States
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Institut Bergonié, Bordeaux, France
- Hôpital Paris Saint Joseph, Paris, France
- Institut Gustave Roussy, Villejuif, France
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
Who to contact
TOAD Clinical Operations · 41 41 556 64 01 · contact@toadonco.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07258407.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.